News Pflash...Pfizer Reminds Us Who The Leader Is In Primary Care

Research evidence excerpt

News Pflash...Pfizer Reminds Us Who The Leader Is In Primary Care

Pharmaceuticals (Major) & Large Cap Biotechnology

Pharmaceuticals - Major - Market Weight

News Pflash...Pfizer Reminds Us Who The Leader Is In June 6, 2026

Primary Care

Pfizer (PFE)

The Wolfe Byte

PFE underlined its commercial prowess in the PCP setting, which we'd agree with given its success with Lipitor,

Viagra, Prevnar & Eliquis. It laid out details on commercial rollout, emphasized its COGS advantage, and drove

home berobenatide's efficacy & tolerability profile.

Pfizer Pflash highlighted its competitiveness against current market leaders given berobenatide's profile and the

company's leading primary care commercial team. There were three main points highlighted during the Pfizer Pflash

that we think the company tried to drive home as reasons why it might be able to differentiate itself on the market when

berobenatide (and earlier stage Metsera offerings) potentially receive approval.

1. Pfizer's primary care sales force. PFE highlighted its #1 ranking per IQVIA's sales force rankings, which it has

maintained for seven consecutive years. Upon approval, the company looks to leverage a direct-to-consumer e-

commerce model as soon as Day 1, be competitive in the cash-pay market, and bring forth a commercial model that

revolves around persistence (i.e., not just therapy starts). The company further highlighted its prior successes competing

in the primary care market in areas such as statins, pneumococcal vaccines, and migraine, where it wasn't always first to

market. On advertising, too, PFE has demonstrated its edge by looking at their ROI which is double that of its benchmarks.

Finally, PFE's relationships with primary care prescribers are deep given that the tenure of the company's field reps is